{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.8","upperLimit":"86.9","value":"78.5"},{"comment":"NA: Confidence Interval could not be calculated for only 1 participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"These are participants who had a day 28 response (CR or CRi response) by IRC assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"NUMBER","populationDescription":"FAS: The Full analysis set comprised all patients who received infusion of tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"1 month","title":"Percentage of Participants Attaining CR or CRi at Day 28 +/- 4 Days Post Tisagenlecleucel (CTL019) Infusion by IRC Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}